This study is for people who finished earlier studies about a medicine called KarXT, aimed at helping with psychosis (a mental disorder where reality might seem different) in Alzheimer's Disease. Alzheimer's is a condition that affects memory and thinking. This is an open-label study, which means both the doctors and participants know what treatment is being given. The study will run for a year (52 weeks) to check if KarXT is safe and works well over a long time.

• This study lasts for 52 weeks.
• You must have completed one of the previous studies (CN012-0026, CN012-0027, or CN012-0056) to join.
• Participants must be between 55 and 90 years old and have a caregiver to help them.

Only people who have completed the earlier studies and are healthy enough can join. The study checks for safety risks, like heart issues, through tests and exams. Participants cannot join if they are part of another study or have serious health problems. It's important for participants to understand what the study is about and agree to join it.